Evidence-Based Reviews

Treating methamphetamine abuse disorder: Experience from research and practice

Current Psychiatry. 2014 September;13(9):36-42, 44

References

1. UNODC. World Drug Report 2012 (United Nations publication, Sales No. E.12.XI.1). http://www.unodc. org/documents/data-and-analysis/WDR2012/ WDR_2012_web_small.pdf. Published 2012. Accessed August 4, 2014.
2. UNODC. World Drug Report 2010 (United Nations publication, Sales No. E.10.XI.13). http://www.unodc. org/documents/wdr/WDR_2010/World_Drug_ Report_2010_lo-res.pdf. Published 2010. Accessed August 4, 2014.
3. Rawson RA, Gonzales R, Brecht M, et al. Evaluation of the California Outcomes Measurement System (CalOMS): Final Report 2008. http://www.uclaisap.org/assets/documents/ California-ADP-DHCS-Evals/2007-2008_CalOMS%20 Report.pdf. Published 2008. Accessed August 4, 2014.
4. Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database Syst Rev. 2009;(1):CD003026.
5. Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai. 2005;88(suppl 3):S43-S52.
6. McKetin R, McLaren J, Lubman D, et al. The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006;101(10):1473-1478.
7. Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008;33(5):1162-1170.
8. McCann DJ, Li SH. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther. 2012;18(5):414-418.
9. Tiihonen J, Kuoppasalmi K, Föhr J, et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry. 2007;164(1): 160-162.
10. Miles SW, Sheridan J, Russell B, et al. Extended-release methylphenidate for treatment of amphetamine/ methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013;108(7): 1279-1286.
11. Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction. 2014;109(9): 1489-1500.
12. Colfax GN, Santos GM, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68(11):1168-1175.
13. Heinzerling KG, Swanson AN, Kim S, et al. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2010;109(1-3):20-29.
14. Galloway GP, Buscemi R, Coyle JR, et al. A randomized, placebo-controlled trial of sustained-release dextro-amphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther. 2011;89(2):276-282.
15. Snider SE, Hendrick ES, Beardsley PM. Glial cell modulators attenuate methamphetamine self-administration in the rat. Eur J Pharmacol. 2013;701(1-3):124-130.
16. Ling W, Rawson R, Shoptaw S. Management of methamphetamine abuse and dependence. Curr Psychiatry Rep. 2006;8(5):345-354.
17. Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract. 2011;24(6):541-550.
18. Jayaram-Lindström N, Wennberg P, Beck O, et al. An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability. Nord J Psychiatry. 2005;59(3):167-171.
19. Jayaram-Lindström N, Konstenius M, Eksborg S, et al. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology. 2007;33(8):1856-1863.
20. Jayaram-Lindström N, Hammarberg A, Beck O, et al. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry. 2008;165(11):1442-1448.
21. Woody GE, Tyrfingsoon P. Symposium XI: Emerging data on efficacy and clinical applications of extended-release naltrexone formulations. 75th Annual Meeting, College on Problems of Drug Dependence. June 19, 2013; San Diego, CA.
22. Newman AH, Blaylock BL, Nader MA, et al. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. Biochem Pharmacol. 2012;84(7):882-890.
23. Verrico CD, Mahoney JJ 3rd, Thompson-Lake DG, et al. Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2014;17(2):223-233.
24. Miller ML, Moreno AY, Aarde S, et al. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry. 2013;73(8):721-728.
25. Shen XY, Kosten TA, Lopez AY, et al. A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Depend. 2013;129(1-2):41-48.
26. Seminerio MJ, Robson MJ, Abdelazeem AH, et al. Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine. AAPS J. 2012;14(1):43-51.
27. Rawson RA, Marinelli-Casey P, Anglin M, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99(6):708-717.
28. Vocci FJ, Montoya ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr Opin Psychiatry. 2009;22(3):263-268.
29. Rawson RA, McCann MJ, Flammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006;101(2):267-274.
30. Roll JM, Petry NM, Stitzer ML, et al. Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry. 2006;163(11):1993-1999.
31. Brecht ML, von Mayrhauser C, Anglin MD. Predictors of relapse after treatment for methamphetamine use. J Psychoactive Drugs. 2000;32(2):211-220.
32. Smout MF, Longo M, Harrison S, et al. Psychosocial treatment for methamphetamine use disorders: a preliminary randomized controlled trial of cognitive behavior therapy and Acceptance and Commitment Therapy. Subst Abus. 2010;31(2):98-107.
33. Wang G, Shi J, Chen N, et al. Effects of length of abstinence on decision-making and craving in methamphetamine abusers. PLoS One. 2013;24;8(7):e68791. doi: 10.1371/ journal.pone.0068791.
34. McKetin R, Lubman DI, Baker AL, et al. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry. 2013;70(3):319-324.
35. Henry BL, Minassian A, Perry W. Effect of methamphetamine dependence on everyday functional ability. Addict Behav. 2010;35(6):593-598.
36. Dean AC, Sevak RJ, Monterosso JR, et al. Acute modafinil effects on attention and inhibitory control in methamphetamine-dependent humans. J Stud Alcohol Drugs. 2011;72(6):943-953.
37. Zullino DF, Benguettat D, Khazaal Y. Improvement of cognitive performance by topiramate: blockage of automatic processes may be the underlying mechanism [Comment on: Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry. 2007.] Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):787.
38. Witkiewitz K, Lustyk M, Bowen S. Retraining the addicted brain: a review of hypothesized neurobiological mechanisms of mindfulness-based relapse prevention. Psychol Addict Behav. 2013;27(2):351-365.

Treating methamphetamine abuse disorder: Experience from research and practice

References

Pages

Recommended Reading

Related Articles

Pearls

Bupropion: Off-label treatment for cocaine and methamphetamine addiction

Commentary

'Meth' and psychosis